Bill of Health
JANUARY 29, 2024
In 2013, for instance, I published an essay titled “ A Declaration of Psychedelic Studies ,” which began with these words: “The scientific research community is in the midst of a ‘psychedelic renaissance,’ but sanctioned platforms for mainstream discussion are heavily weighted in the direction of objective scientific research.
Bill of Health
APRIL 7, 2022
(he/him or they/them) has been personally utilizing psychedelics and other substances in celebratory and spiritual contexts for over fifteen years, and has been actively participating in the drug policy reform movement since 2013.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SQA
MAY 17, 2022
ANVISA’s RDC 665/2022 (link in Portuguese) replaces previous regulations, including RDC 16/2013 and IN 08/2013, and went into effect on 02 May 2022. ANVISA has issued a new resolution that updates Brazilian Good Manufacturing Practices (BGMP) for medical devices and in vitro diagnostic (IVD) products.
Bill of Health
AUGUST 29, 2022
439, 448 (2013). [15] Sugarman, 566 F.2d 2d 817, 825 (2d Cir. 13] San Antonio Indep. Rodriguez, 411 U.S. 1, 35 (1973). [14] 14] Erin C. Fuse Brown, Developing a Durable Right to Health Care , 14 Minn. & Tech. 15] Emily Parker, Constitutional Obligations for Public Education , Educ.
Drug & Device Law
DECEMBER 21, 2023
Bexis’ amicus efforts this year in Mallory obviously came to naught, and we’ve had our own cases on this list before (see, e.g. , 2013-2 and 2021-10 ). If you’ve been burned by any of these judicial debacles, we sympathize. A lawyer who never loses doesn’t litigate hard cases. The penalty did not hold up, but the duty did.
Drug & Device Law
MAY 25, 2023
Another motion reflected Bexis original position (but wasn’t Bexis’ motion), that the Institute should prepare black letter, comments and reporters’ notes for both sides of this issue, similarly to the manner in which the same draft handled the question of patient-oriented versus physician-oriented standards for informed consent.
Drug & Device Law
MAY 30, 2022
2013 WL 2457950, at *8 (N.D. June 6, 2013) (no causation where the prescriber “believed that any risk associated with the drug was heavily outweighed by the benefits of treating what he suspected was. . . 2014); In re Trasylol Products Liability Litigation , 2013 WL 1080552 at *12 (S.D. 2013 WL 1758647, at *5 (D.N.J.
Expert insights. Personalized for you.
355 
Let's personalize your content